Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses

Area of Science:

• Oncology
• Virology
• Vascular Biology

Background:

• Tumor blood supply fuels cancer progression and metastasis.
• Current anti-cancer therapies targeting tumor vasculature have limited effectiveness due to indirect cell death.
• Combined strategies to disrupt tumor vasculature and kill cancer cells are needed.

Purpose of the Study:

• To review preclinical and clinical evidence of oncolytic viruses' antitumor vascular effects.
• To explore the mechanisms by which oncolytic viruses impact tumor vasculature.
• To assess the potential of oncolytic virotherapy as a standalone or combination therapy.

Main Methods:

• Review of preclinical studies on oncolytic virus-induced vascular disruption.
• Analysis of clinical trial data on oncolytic virotherapy and vascular effects.
• Examination of viral mechanisms targeting tumor endothelial cells.
• Evaluation of oncolytic viruses' antiangiogenic properties.
• Assessment of combination therapies with approved antivascular agents.

Main Results:

• Oncolytic viruses can infect and lyse tumor endothelial cells, disrupting tumor vasculature.
• Some oncolytic viruses possess natural or engineered antiangiogenic properties.
• Combination therapy with oncolytic viruses and antivascular agents shows enhanced efficacy.
• Oncolytic virotherapy induces direct tumor cell lysis and stimulates antitumor immunity.

Conclusions:

• Oncolytic viruses demonstrate significant potential in targeting and disrupting tumor vasculature.
• Their multifaceted mechanisms, including vascular effects, offer a promising therapeutic strategy.
• Further clinical investigation and combination strategies are warranted to optimize oncolytic virotherapy outcomes.